The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells

About 20% of breast cancers are characterized by amplification and overexpression of the HER2 oncogene. Although significant progress has been achieved for treating such patients with HER2 inhibitor trastuzumab, more than half of the patients respond poorly or become resistant to the treatment. Sinc...

詳細記述

保存先:
書誌詳細
出版年:Mol Oncol
主要な著者: Sahlberg, Kristine Kleivi, Hongisto, Vesa, Edgren, Henrik, Mäkelä, Rami, Hellström, Kirsi, Due, Eldri U., Moen Vollan, Hans Kristian, Sahlberg, Niko, Wolf, Maija, Børresen-Dale, Anne-Lise, Perälä, Merja, Kallioniemi, Olli
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2012
主題:
Papers
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528495/
https://ncbi.nlm.nih.gov/pubmed/23253899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.10.012
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料